Scientists Thought Parkinson's Was in Our Genes. New ideas about chronic illness could revolutionize treatment, if we take the research seriously. Amy Lindberg spent 26 years in the Navy and she still walked like it--with intention, like her chin had someplace to be. But around 2017, her right foot stopped following orders. Lindberg and her husband Brad were five years into their retirement. After moving 10 times for Uncle Sam, they'd bought their dream house near the North Carolina coast. They had a backyard that spilled out onto wetlands. From the kitchen, you could see cranes hunting. They kept bees and played pickleball and watched their children grow. But now Lindberg's right foot was out of rhythm. She worked hard to ignore it, but she couldn't disregard the tremors.

AI is a magnificent field that directly and profoundly touches on numerous disciplines ranging from philosophy, computer science, engineering, mathematics, decision and data science and economics, to cognitive science, neuroscience and more. The number of applications and impact of AI is second to none and the potential of AI to broadly impact future science developments is particularly thrilling. While attempts to understand knowledge, reasoning, cognition and learning go back centuries, AI remains a relatively new field. In part due to the fact it has so many wide-ranging overlaps with other disparate fields it appears to have trouble developing a robust identity and culture. Here we suggest that contrasting the fast-moving AI culture to biological and biomedical sciences is both insightful and useful way to inaugurate a healthy tradition needed to envision and manage our ascent to AGI and beyond (independent of the AI Platforms used). The co-evolution of AI and Biomedical Science offers many benefits to both fields. In a previous perspective, we suggested that biomedical laboratories or centers can usefully embrace logistic traditions in AI labs that will allow them to be highly collaborative, improve the reproducibility of research, reduce risk aversion and produce faster mentorship pathways for PhDs and fellows. This perspective focuses on the benefits to AI by adapting features of biomedical science at higher, primarily cultural levels.

We start off the new year with good budgetary news and profound gratitude to the U.S. Congress for providing NIH and NHGRI a healthy Fiscal Year 2023 budget. Specifically, NIH received a roughly 5.6% increase, while NHGRI received a roughly 3.8% increase. The latter will help provide the fuel we need for bringing another year of spectacular NHGRI-supported genomics breakthroughs! Meanwhile, let's also start the new year with some simple questions. First: what is 2,023 minus 2,003?

Whether we realize it or not, most of us deal with artificial intelligence (AI) every day. Each time you do a Google Search or ask Siri a question, you are using AI. The catch, however, is that the intelligence these tools provide is not really intelligent. They don't truly think or understand in the way humans do. Rather, they analyze massive data sets, looking for patterns and correlations.

The past decade has seen an important and, for many patients, a life-changing rise in the number of innovative new drugs reaching the market to treat diseases such as multiple sclerosis, malaria, and subtypes of certain cancers (such as melanoma or leukemia). In the United States, the Food and Drug Administration approved an average of 41 new molecular entities (including biologic license applications) each year from 2011 to 2020--almost double the number in the previous decade. Despite the immense costs of such achievements, 2 2. Asher Mullard, "New drugs cost US $2.6 billion to develop," Nature Reviews Drug Discovery, December 1, 2014. A major barrier is the daunting challenge of understanding the multifactorial nature of many diseases coupled with the vast set of variables in therapy design. Very few diseases, such as cystic fibrosis, are linked to variants in single genes. Drug development therefore tends to rely on a reductionist, hypothesis-driven approach that narrows the focus to individual cell types or pathways. Focused assays often based on partial information or informed by animal models that never perfectly reflect human disease then attempt to identify single molecules that will benefit patients.

Working with researchers on both sides of the Atlantic, he has found a few good options. But his task is that of the most demanding locksmith: to pinpoint the chemical compounds that on their own will twist and fold into the microscopic shape that can fit perfectly into the molecules of a plastic bottle and split them apart, like a key opening a door. Determining the exact chemical contents of any given enzyme is a fairly simple challenge these days. But identifying its 3D shape can involve years of biochemical experimentation. So last fall, after reading that an artificial intelligence lab in London called DeepMind had built a system that automatically predicts the shapes of enzymes and other proteins, McGeehan asked the lab if it could help with his project.

The hope of The Human Genome Project was that it would herald a new age of precision medicine. However, the challenge turned out to be more complex and nuanced than had been imagined. Of nearly 25,000 human genes, only 2,418 have been associated with specific diseases, explaining only a small fraction of all human pathologies. In 2020, we will begin to harness the power of artificial intelligence (AI) to create new, life-saving medicine. In the past decade, we have learned a great deal about the complexity of diseases.

While artificial intelligence has tremendous potential for revolutionizing healthcare delivery, there are many possible pitfalls and ill-intended uses of this powerful technology. "With the great promise of AI comes an even greater responsibility," Tourassi testified on Wednesday before a House committee hearing on AI's societal and ethical implications. "There are many ethical questions when applying AI in medicine." With respect to ethics, she observed that the massive volumes of health data being leveraged by AI must be carefully protected to preserve privacy. "The sheer volume, variability and sensitive nature of the personal data being collected require newer, extensive, secure and sustainable computational infrastructure and algorithms," according to Tourassi's testimony.

Almost 20 years ago, the medical and scientific communities were overjoyed. With the Human Genome Project finished, there was an air of inevitability that the causes of some of the most common and destructive diseases would soon be pinpointed and eradicated. It'd be simple: one gene, one problem, one solution. We even heard Francis Collins, at the time, say "over the longer term, perhaps in another 15 or 20 years, you will see a complete transformation in therapeutic medicine." Unfortunately, it was never going to be that easy.

She is, in her own words, an "old-school biologist", brought up on the skills of pipettes and Petri dishes and protective goggles, the science of experiments with glassware on benches – what's known as "wet lab" work. "I knew what a gene looked like on a gel," she says, thinking back to her early career. These days that skill set is not enough. "When I started hiring PhD students 15 years ago, they were entirely wet lab," Corcoran says. "Now when we recruit them, the first thing we look for is if they can cope with complex bioinformatic analysis." To be a biologist, nowadays, you need to be a statistician, or even a programmer. You need to be able to work with algorithms. An algorithm, essentially, is a set of instructions – a series of predefined steps. A recipe could be seen as an algorithm, although a more obvious example is a computer program.